mTOR inhibition improves immune function in the elderly
- PMID: 25540326
- DOI: 10.1126/scitranslmed.3009892
mTOR inhibition improves immune function in the elderly
Abstract
Inhibition of the mammalian target of rapamycin (mTOR) pathway extends life span in all species studied to date, and in mice delays the onset of age-related diseases and comorbidities. However, it is unknown if mTOR inhibition affects aging or its consequences in humans. To begin to assess the effects of mTOR inhibition on human aging-related conditions, we evaluated whether the mTOR inhibitor RAD001 ameliorated immunosenescence (the decline in immune function during aging) in elderly volunteers, as assessed by their response to influenza vaccination. RAD001 enhanced the response to the influenza vaccine by about 20% at doses that were relatively well tolerated. RAD001 also reduced the percentage of CD4 and CD8 T lymphocytes expressing the programmed death-1 (PD-1) receptor, which inhibits T cell signaling and is more highly expressed with age. These results raise the possibility that mTOR inhibition may have beneficial effects on immunosenescence in the elderly.
Copyright © 2014, American Association for the Advancement of Science.
Comment in
-
Aging interventions get human.Oncotarget. 2015 Jan 20;6(2):590-1. doi: 10.18632/oncotarget.3173. Oncotarget. 2015. PMID: 25612254 Free PMC article. No abstract available.
Similar articles
-
Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice.Aging Cell. 2015 Dec;14(6):945-56. doi: 10.1111/acel.12380. Epub 2015 Aug 28. Aging Cell. 2015. PMID: 26315673 Free PMC article.
-
Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor.Mol Cell Endocrinol. 2012 Mar 5;350(1):99-106. doi: 10.1016/j.mce.2011.11.024. Epub 2011 Dec 8. Mol Cell Endocrinol. 2012. PMID: 22178087
-
Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.Cancer. 2011 Sep 15;117(18):4141-54. doi: 10.1002/cncr.26011. Epub 2011 Mar 8. Cancer. 2011. PMID: 21387274
-
mTOR kinase inhibitors as a treatment strategy in hematological malignancies.Future Med Chem. 2012 Mar;4(4):487-504. doi: 10.4155/fmc.12.14. Future Med Chem. 2012. PMID: 22416776 Review.
-
Differing effects of rapamycin and mTOR kinase inhibitors on protein synthesis.Biochem Soc Trans. 2011 Apr;39(2):446-50. doi: 10.1042/BST0390446. Biochem Soc Trans. 2011. PMID: 21428917 Review.
Cited by
-
Comparison of the effect of Everolimus, Prednisolone, and a combination of both on experimentally induced peritoneal adhesions in rats.Sci Rep. 2024 May 14;14(1):11077. doi: 10.1038/s41598-024-61620-3. Sci Rep. 2024. PMID: 38745015 Free PMC article.
-
Regulation of fatty acid delivery to metastases by tumor endothelium.bioRxiv [Preprint]. 2024 Apr 3:2024.04.02.587724. doi: 10.1101/2024.04.02.587724. bioRxiv. 2024. PMID: 38617241 Free PMC article. Preprint.
-
Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies.NPJ Vaccines. 2024 Apr 10;9(1):77. doi: 10.1038/s41541-024-00874-4. NPJ Vaccines. 2024. PMID: 38600250 Free PMC article. Review.
-
Evaluating the effect of rapamycin treatment in Alzheimer's disease and aging using in vivo imaging: the ERAP phase IIa clinical study protocol.BMC Neurol. 2024 Apr 4;24(1):111. doi: 10.1186/s12883-024-03596-1. BMC Neurol. 2024. PMID: 38575854 Free PMC article.
-
Impact of Immunosenescence in Older Kidney Transplant Recipients: Associated Clinical Outcomes and Possible Risk Stratification for Immunosuppression Reduction.Drugs Aging. 2024 Mar;41(3):219-238. doi: 10.1007/s40266-024-01100-5. Epub 2024 Feb 22. Drugs Aging. 2024. PMID: 38386164 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
